Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Oct 19;22(3):432–440. doi: 10.1016/j.bbmt.2015.10.005

Fig 2. Allogeneic hematopoietic cell transplantation (HCT) outcomes by response to prior JAK1/2 inhibitor therapy.

Fig 2

Group-A: patients who experienced clinical improvement with JAK1/2 inhibitors, Group -E: patients who developed leukemic transformation while on JAK1/2 inhibitor therapy, and Group -BCD: combined group of others. (A) Probability of overall survival (OS), (B) cumulative incidence of non relapse mortality (NRM) and, (C) cumulative incidence of relapse / progression